Sickle Cell Gene Therapies Seen as Cost Effective Below $2M Threshold: Study

Gene therapies for sickle cell disease are likely to be cost-effective in the U.S. when priced below $2 million, according to a new study published Tuesday in the journal Annals of Internal Medicine.